Merck has reported positive data from a pivotal Phase II trial (KEYNOTE-002) of its anti-PD-1 therapy pembrolizumab in patients with ipilimumab-refractory advanced melanoma.
Pembrolizumab is a humanised monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
Go deeper with GlobalData
The global, randomised Phase II KEYNOTE-002 trial evaluated pembrolizumab at doses of 2mg/kg every three weeks and 10mg/kg every three weeks compared to investigator’s choice chemotherapy (paclitaxel plus carboplatin, paclitaxel, carboplatin, dacarbazine or temozolomide) in these patients.
The trial showed that pembrolizumab improved the primary endpoint of progression-free survival (PFS), compared to chemotherapy.
In the trial, 83% of patients had the most advanced stage of disease (M1c) and 73% of patients had received at least two prior systemic therapies including ipilimumab.
The co-primary endpoints of the trial were PFS and overall survival, while secondary endpoints included overall response rate (ORR), duration of response and safety; and health-related quality of life (HRQoL) as a pre-specified exploratory endpoint.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataMerck Research Laboratories vice-president of global clinical development for oncology Dr Eric Rubin said: "These findings demonstrate pembrolizumab was superior to chemotherapy in helping more patients with ipilimumab-refractory advanced melanoma achieve progression-free survival.
"The comparative efficacy and safety data from the pivotal KEYNOTE-002 study validate and extend the findings from our earlier study in these difficult-to-treat patients, and we look forward to sharing data on overall survival at a future congress."
The company said that the objective of the pre-specified analysis was to assess the superiority of either dose of Keytruda over chemotherapy for PFS.
The trial was designed with co-primary endpoints of PFS and overall survival and an evaluation of overall survival is planned at the pre-specified final analysis in 2015.
In a pre-specified analysis for HRQoL, patients treated with pembrolizumab reported a significantly smaller decrement in health status/quality of life score compared to those treated with chemotherapy.
Image: Melanoma in skin biopsy with H&E stain — this case may represent superficial spreading melanoma. Photo: courtesy of KGH.
